PARLIAMENTARY WRITTEN QUESTION
(6 December 2024)

There are ongoing global supply issues with some medications used to treat diabetes, and we continue to work closely with industry partners to improve the situation. Supplies of Rybelsus, which is an oral semaglutide available in tablet form, have been boosted to support demand from new patients with type 2 diabetes, as well as those unable to obtain their existing treatment. The Medicines and Healthcare products Regulatory Agency’s regulatory approval of Mounjaro, an injectable medicine for adults with type 2 diabetes, has brought an additional treatment option to the United Kingdom’s market. We have provided advice for healthcare professionals on how to manage patients requiring these medicines whilst there are shortages, and are keeping this under review as the situation evolves. The Department has also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the UK.

The guidance is clear that medications licensed to treat type 2 diabetes should not be prescribed for weight loss, except where specifically licenced for this use. Any patient who is worried about their condition, or access to these medications, should speak to their clinician in the first instance.

The Department monitors and manages medicine supply at a national level, so that stocks remain available to meet regional and local demand. Information on stock levels within individual pharmacies is not held centrally.